JME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1677/jme.0.0310061

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bollheimer, L.
Right arrow Articles by Buettner, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bollheimer, L.
Right arrow Articles by Buettner, R
Journal of Molecular Endocrinology, Vol 31, Issue 1, 61-69
Copyright © 2003 by Society for Endocrinology


Articles

Insulin-sparing effects of troglitazone in rat pancreatic islets

LC Bollheimer, S Troll, H Landauer, CE Wrede, J Scholmerich, and R Buettner


Thiazolidinediones (TZDs) have been suggested to act beneficially on pancreatic islet function and on beta-cell viability but data concerning direct effects on isolated islets are controversial. Therefore, we have examined parameters of pancreatic insulin and glucagon secretion and biosynthesis in TZD-exposed rat pancreatic islets under physiological glucose level conditions and under conditions of glucolipotoxicity. Primary rat islets were incubated for 2.5 h with or without troglitazone (10 microM) in 5.6 mM glucose (standard glucose levels) and 16.7 mM glucose (high glucose levels); a subgroup was additionally treated with oleate (200 microM) to simulate acute glucolipotoxicity. Insulin and glucagon secretion, intracellular content and their respective mRNAs were quantified. Newly synthesized insulin was determined by pulse-labeling experiments. Troglitazone reduced insulin secretion at standard and high glucose levels by about one-third (P


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. Buettner, I. Ottinger, C. Gerhardt-Salbert, C. E. Wrede, J. Scholmerich, and L. C. Bollheimer
Antisense oligonucleotides against the lipid phosphatase SHIP2 improve muscle insulin sensitivity in a dietary rat model of the metabolic syndrome
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1871 - E1878.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
R Buettner, K G Parhofer, M Woenckhaus, C E Wrede, L A Kunz-Schughart, J Scholmerich, and L C Bollheimer
Defining high-fat-diet rat models: metabolic and molecular effects of different fat types.
J. Mol. Endocrinol., June 1, 2006; 36(3): 485 - 501.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
L. E. Parton, F. Diraison, S. E. Neill, S. K. Ghosh, M. A. Rubino, J. E. Bisi, C. P. Briscoe, and G. A. Rutter
Impact of PPAR{gamma} overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays
Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E390 - E404.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Society for Endocrinology.